Utah Retirement Systems Sells 200 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Utah Retirement Systems trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.5% in the 4th quarter, Holdings Channel reports. The firm owned 13,438 shares of the company’s stock after selling 200 shares during the quarter. Utah Retirement Systems’ holdings in IDEXX Laboratories were worth $5,556,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Insight Wealth Strategies LLC lifted its holdings in IDEXX Laboratories by 230.5% during the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after buying an additional 7,041 shares in the last quarter. Sax Wealth Advisors LLC raised its stake in shares of IDEXX Laboratories by 76.3% during the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock valued at $590,000 after acquiring an additional 617 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of IDEXX Laboratories by 11.5% in the fourth quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock valued at $3,199,000 after purchasing an additional 800 shares during the period. Paragon Capital Management Inc. grew its stake in IDEXX Laboratories by 25.7% in the fourth quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company’s stock worth $1,579,000 after purchasing an additional 782 shares in the last quarter. Finally, Manitou Investment Management Ltd. increased its holdings in IDEXX Laboratories by 491.0% during the 4th quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company’s stock worth $21,582,000 after purchasing an additional 43,369 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IDXX has been the topic of a number of recent research reports. Morgan Stanley dropped their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a report on Monday, April 14th. Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Finally, Bank of America boosted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $523.75.

Insider Buying and Selling

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $471.38 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $548.88. The firm’s fifty day simple moving average is $419.02 and its two-hundred day simple moving average is $428.54. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $38.20 billion, a P/E ratio of 44.18, a P/E/G ratio of 3.41 and a beta of 1.50.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period in the prior year, the company posted $2.71 EPS. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.